DDrare: Database of Drug Development for Rare Diseases

114. 非ジストロフィー性ミオトニー症候群
［臨床試験数：10，薬物数：14（DrugBank：5），標的遺伝子数：18，標的パスウェイ数：10］

Searched query = "Non-dystrophic myotonia syndrome", "Non-dystrophic Myotonia", "Myotonia congenita", "Thomsen disease", "Becker disease", "Paramyotonia congenita", "Sodium channel myotonia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AL; Dichlorphenamide; LAMOTRIGINE; Lamotrigin actavis; Lamotrigine; MEXILETINA CLORIDRATO; MEXILETINE; MEXITIL*20CPS 200MG; Mexiletina; Mexiletine; Mexitil; RILUZOLO; RILUZOLO TEVA - 50 MG COMPRESSE RIVESTITE CON FILM 90 COMPRESSE IN BLISTER AL/PVC; Ranolazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01939561 (ClinicalTrials.gov)	November 2013	23/8/2013	Lamotrigine as Treatment of Myotonia	Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study	Dystrophia Myotonica Type 1;Myotonia Congenita;Paramyotonia Congenita;Hyperkalemic Periodic Paralysis;Potassium-Aggravated Myotonia	Drug: Lamotrigine;Drug: Placebo	Grete Andersen, MD	NULL	Completed	18 Years	N/A	Both	27	Phase 3	Denmark
2	EUCTR2013-003309-24-DK (EUCTR)	28/10/2013	21/10/2013	Better treatment of muscle diseases	Lamotrigine as treatment of Myotonia	Myotonia is a symptom seen certain inherited muscle dystrophies and pure channelopathies (Dystrophia myotonica type 1 and 2, Myotonia Congenita, Paramyotonia Congenita, Hyperkalæmisk periodic paralysis and Potassium-Aggravated myotonia). Genetically, mutations in chloride, sodium or calcium ion channels in the muscle is present. Myotonia manifests during physical activity where the muscle can locks in the middle of a movement. Patients are limited in their physical as well as social activities. MedDRA version: 14.1;Level: PT;Classification code 10061533;Term: Myotonia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Lamotrigin actavis INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE	Grete Andersen	NULL	Not Recruiting			Female: yes Male: yes			Denmark

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01939561
(ClinicalTrials.gov)

November 2013

23/8/2013

Lamotrigine as Treatment of Myotonia

Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study

Dystrophia Myotonica Type 1;Myotonia Congenita;Paramyotonia Congenita;Hyperkalemic Periodic Paralysis;Potassium-Aggravated Myotonia

Drug: Lamotrigine;Drug: Placebo

Grete Andersen, MD

NULL

Completed

18 Years

N/A

Both

Phase 3

Denmark

EUCTR2013-003309-24-DK
(EUCTR)

28/10/2013

21/10/2013

Better treatment of muscle diseases

Lamotrigine as treatment of Myotonia

Myotonia is a symptom seen certain inherited muscle dystrophies and pure channelopathies (Dystrophia myotonica type 1 and 2, Myotonia Congenita, Paramyotonia Congenita, Hyperkalæmisk periodic paralysis and Potassium-Aggravated myotonia). Genetically, mutations in chloride, sodium or calcium ion channels in the muscle is present. Myotonia manifests during physical activity where the muscle can locks in the middle of a movement. Patients are limited in their physical as well as social activities.
MedDRA version: 14.1;Level: PT;Classification code 10061533;Term: Myotonia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

Trade Name: Lamotrigin actavis
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE

Grete Andersen

NULL

Not Recruiting

Female: yes
Male: yes

Denmark